secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001171843-23-001058
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q4 ORLADEYO revenue $70.7M; FY 2022 revenue $270.8M; 2023 guidance ≥$320M
--------------------------------------------------------------------------------

- ORLADEYO net revenue $70.7M in Q4 2022, $251.6M for FY 2022; 2023 guidance no less than $320M.
- Total Q4 revenue $79.5M (+68% YoY); net loss $71.5M ($0.38/share) vs $17.8M ($0.10) in Q4 2021 (incl. $55.8M gain).
- Full year net loss $247.1M ($1.33/share) vs $184.1M ($1.03) in 2021; cash $443.9M at Dec 31, 2022.
- Complement inhibitor program delayed due to nonclinical study observations; BCX10013 phase 1 showed >97% AP suppression.
- ORLADEYO peak sales expected $1B; Canadian positive reimbursement recommendation received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/0001171843-23-001058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323001058/f8k_022123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer